复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药

阿斯达克财经08-08

复宏汉霖(02696.HK) 公布，HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的II期临床研究于内地完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2458346994?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","is_english":false,"pubTime":"2024-08-08 23:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2458346994","market":"other","top_or_hot":-1,"title":"复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药","media":"阿斯达克财经","content":"<div>\n<p>复宏汉霖(02696.HK) 公布，HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的II期临床研究于内地完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1370141/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696.HK)HLX53联合汉斯状及汉贝泰临床研究完成首例患者给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-08 23:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1370141/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复宏汉霖(02696.HK) 公布，HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的II期临床研究于内地完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1370141/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1370141/latest-news/AAFN","article_id":"2458346994","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458346994","pubTimestamp":1723132560,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"复宏汉霖(02696.HK) 公布，HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的II期临床研究于内地完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"Henlius (02696. HK) HLX53 combined with Hans and Hanbetai clinical study completed the first patient administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"复宏汉霖(02696.HK) 公布，HLX53联合汉斯状及汉贝泰一线治疗局部晚期或转移性肝细胞癌的II期临床研究于内地完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458346994"}